|By PR Newswire||
|April 17, 2014 05:18 PM EDT||
QUEBEC CITY, April 17, 2014 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation") today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated March 14, 2014 and put forth for vote during the shareholders meeting held today in Montreal.
Shareholders re-elected Dr. Yves Fradet, Dr. Louise Proulx, Mr. Andrew Sheldon, Dr. Jacques Simoneau, and Dr. Vincent R. Zurawski as directors of the Corporation.
The election results for the Board of directors are as follows:
|Nominees||For (%)||Withheld (%)|
|Andrew J. Sheldon||70.04||29.96|
|Vincent R. Zurawski||69.54||30.46|
Shareholders also reappointed Ernst & Young as auditors of the Corporation and reconfirmed DiagnoCure's Shareholders Rights Plan.
The presentation given by Dr. Yves Fradet after completion of the formal business portion of the meeting today is available on DiagnoCure's website at www.diagnocure.com through a link on the Investors page; Presentations.
"DiagnoCure's primary focus is to secure shareholder value by ensuring the full commercial potential of PCA3". stated Dr. Yves Fradet. Chairman of the Board and President and Chief Medical Officer of the Corporation.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008. the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe. now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information. please visit www.diagnocure.com.
This release may contain forward‐looking statements that involve known and unknown risks. uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates". "assumes". "believes". "estimates". "expects". "intend". "may". "plans". "projects". "should". "will". or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature. forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties. known and unknown. many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives. strategic priorities. expectations and plans. and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forward‐looking statements. For instance. any forward-looking statements regarding the outcome of research and development projects. clinical studies and future revenues. including those related to PROGENSA® PCA3. are based on management expectations and such outcome may vary materially depending on global political and economic conditions. dependence on collaboration partners. uncertainty of healthcare reimbursement. and marketing and distribution challenges. In addition. the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
Jul. 25, 2016 02:00 PM EDT Reads: 933
Jul. 25, 2016 01:15 PM EDT Reads: 1,895
Jul. 25, 2016 01:00 PM EDT Reads: 1,924
Jul. 25, 2016 12:15 PM EDT Reads: 411
Jul. 25, 2016 12:00 PM EDT Reads: 1,813
Jul. 25, 2016 12:00 PM EDT Reads: 1,663
Jul. 25, 2016 11:45 AM EDT Reads: 863
Jul. 25, 2016 11:00 AM EDT Reads: 1,574
Jul. 25, 2016 11:00 AM EDT Reads: 898
Jul. 25, 2016 10:53 AM EDT Reads: 327
Jul. 25, 2016 10:30 AM EDT Reads: 1,938
Jul. 25, 2016 10:30 AM EDT Reads: 295
Jul. 25, 2016 10:15 AM EDT Reads: 1,865
Jul. 25, 2016 10:00 AM EDT Reads: 985
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 25, 2016 09:45 AM EDT Reads: 1,669